These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 26443443)

  • 1. Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings.
    Mikkelsen AP; Hansen ML; Olesen JB; Hvidtfeldt MW; Karasoy D; Husted S; Johnsen SP; Brandes A; Gislason G; Torp-Pedersen C; Lamberts M
    Europace; 2016 Apr; 18(4):492-500. PubMed ID: 26443443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR
    Thompson LE; Maddox TM; Lei L; Grunwald GK; Bradley SM; Peterson PN; Masoudi FA; Turchin A; Song Y; Doros G; Davis MB; Daugherty SL
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort.
    Olesen JB; Lip GY; Hansen PR; Lindhardsen J; Ahlehoff O; Andersson C; Weeke P; Hansen ML; Gislason GH; Torp-Pedersen C
    J Thromb Haemost; 2011 Aug; 9(8):1460-7. PubMed ID: 21624047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
    Henk HJ; Cao F; Tuell K; Price K; Singh P; Mardekian J; Odell K; Patel C; Tan W; Sands GH; Singhal S; Trocio J; Vo L
    Curr Med Res Opin; 2018 Mar; 34(3):539-546. PubMed ID: 29235900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
    Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
    Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
    Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A; Lip GY; Bjerregaard Larsen T
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1236-1244. PubMed ID: 27229855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    Thromb Haemost; 2017 Jun; 117(7):1448-1454. PubMed ID: 28331926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
    Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
    Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.
    Polo García J; Vargas Ortega D; Formiga F; Unzueta I; Fernández de Cabo S; Chaves J
    Semergen; 2019 Sep; 45(6):396-405. PubMed ID: 30573367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.
    Gray MP; Saba S; Zhang Y; Hernandez I
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis.
    Bai Y; Guo SD; Deng H; Shantsila A; Fauchier L; Ma CS; Lip GYH
    Age Ageing; 2018 Jan; 47(1):9-17. PubMed ID: 28985259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
    Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis.
    Kim TH; Kim JY; Mun HS; Lee HY; Roh YH; Uhm JS; Pak HN; Lee MH; Joung B
    J Thromb Haemost; 2015 Feb; 13(2):182-90. PubMed ID: 25472735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.